Biontech is investing almost one billion dollars in the expansion of its portfolio of cancer drugs. Biontech is initially putting $800 million on the table for the Chinese biotech company Biotheus, as the Mainz-based company announced on Wednesday. In addition, there will be performance-related payments of up to $150 million. This will give the German biotech company control over a class of drugs that has the potential to outperform Merck’s cancer drug Keytruda.